[Estimation of the clinical and pharmacoeconomic efficiency of treatment in patients with community-acquired pneumonia with third-generation cephalosporins].

The clinical and pharmacoeconomic effectiveness of the third-generation cephalosporin Ceftriabol versus the original drug Claforan in the treatment of varying community-acquired pneumonia was studied in 60 and 58 patients, respectively. The Russian third-generation cephalosporin Ceftriabol was shown to be as effective as Claforan in treating patients with community-acquired pneumonia. However, in addition to the main--therapeutic effect, Ceftriabol produces a certain economic gain.

[Comparative assessment of efficacy of the 3d generation cephalosporins, ceftriabol, and claforan, in patients with community-acquired pneumonia].

The aim of the study was to evaluate therapeutic efficiency of ceftriabol (Russia) and claforan (both 3d generation cefalosporins) used to manage severe extrahospital pneumonia. Ceftriabol (2 g) was administered one or twice daily, claforan intravenously (2 g b.i.d. or t.i.d). Results of the treatment were assessed from a combination of anamnestic and physical examination data, results of X-ray and laboratory studies. Normalization of major clinical, laboratory, and instrumental parameters in patients treated with ceftriabol and claforan was achieved roughly within the same time period. It means that ceftriabol is at least as efficacious as claforan when applied to the treatment of severe extrahospital pneumonia.